文献详情
Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial
文献类型：期刊
通讯作者：He, J; Sun, XL; Li, ZG (reprint author), Peking Univ, Dept Rheumatol & Immunol, Peoples Hosp, Beijing 100044, Peoples R China.; Yu, D (reprint author), Australian Natl Univ, John Curtin Sch Med Res, Dept Immunol & Infect Dis, Canberra, ACT, Australia.
期刊名称：ANNALS OF THE RHEUMATIC DISEASES影响因子和分区
年：2020
卷：79
期：1
页码：141-149
ISSN：0003-4967
所属部门：统计学院
摘要：Objectives Open-labelled clinical trials suggested that low-dose IL-2 might be effective in treatment of systemic lupus erythematosus (SLE). A double-blind and placebo-controlled trial is required to formally evaluate the safety and efficacy of low-dose IL-2 therapy. Methods A randomised, double-blind and placebo-controlled clinical trial was designed to treat 60 patients with active SLE. These patients received either IL-2 (n=30) or placebo (n=30) with standard treatment for 12 weeks, and we ...More
Objectives Open-labelled clinical trials suggested that low-dose IL-2 might be effective in treatment of systemic lupus erythematosus (SLE). A double-blind and placebo-controlled trial is required to formally evaluate the safety and efficacy of low-dose IL-2 therapy. Methods A randomised, double-blind and placebo-controlled clinical trial was designed to treat 60 patients with active SLE. These patients received either IL-2 (n=30) or placebo (n=30) with standard treatment for 12 weeks, and were followed up for additional 12 weeks. IL-2 at a dose of 1 million IU or placebo was administered subcutaneously every other day for 2 weeks and followed by a 2-week break as one treatment cycle. The primary endpoint was the SLE Responder Index-4 (SRI-4) at week 12. The secondary endpoints were other clinical responses, safety and dynamics of immune cell subsets. Results At week 12, the SRI-4 response rates were 55.17% and 30.00% for IL-2 and placebo, respectively (p=0.052). At week 24, the SRI-4 response rate of IL-2 group was 65.52%, compared with 36.67% of the placebo group (p=0.027). The primary endpoint was not met at week 12. Low-dose IL-2 treatment resulted in 53.85% (7/13) complete remission in patients with lupus nephritis, compared with 16.67% (2/12) in the placebo group (p=0.036). No serious infection was observed in the IL-2 group, but two in placebo group. Besides expansion of regulatory T cells, low-dose IL-2 may also sustain cellular immunity with enhanced natural killer cells. Conclusions Low-dose IL-2 might be effective and tolerated in treatment of SLE. ...Hide

DOI：10.1136/annrheumdis-2019-215396
百度学术：Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial
语言：外文
被引频次：1
人气指数：1
浏览次数：1
基金：National Natural Science Foundation of ChinaNational Natural Science Foundation of China [31530020, 31570880, 81471601, 81601417, 81701598]; Peking-Tsinghua Center for Life Sciences [Z171100000417007]; Clinical Medicine Plus X-Young Scholars Project of Peking University - Fundamental Research Funds for the Central Universities [PKU2019LCXQ013]; Beijing Nova ProgramBeijing Municipal Science & Technology Commission [Z171100001117025]; National Key Research and Development Program of China [2017YFC0909003]; Bellberry-Viertel Senior Medical Research Fellowship; Beijing SL PHARM
作者其他论文



SET: Secure and Efficient Top-k Query in Two-Tiered Wireless Sensor Networks.Zhang, Xiaoying, Peng, Hui, Dong, Lei, et al. .WEB AND BIG DATA, APWEB-WAIM 2017, PT I. 2017, 10366, 495-510.
Efficiency evaluation of thermal power plants in China based on the weighted Russell directional distance method.Xie, Jun, Liang, Zhuang, Zhang, Xiaobing, et al. .JOURNAL OF CLEANER PRODUCTION. 2019, 222, 573-583.
Efficiency evaluation of thermal power plants in China based on the weighted Russell directional distance method.Xie, Jun, Liang, Zhuang, Zhang, Xiaobing, et al. .JOURNAL OF CLEANER PRODUCTION. 2019, 222, 573-583.
Medical expenditure for middle-aged and elderly in Beijing.Ma, Chenjin, Jiang, Yan, Li, Yang, et al. .BMC HEALTH SERVICES RESEARCH. 2019, 19.
Medical expenditure for middle-aged and elderly in Beijing.Ma, Chenjin, Jiang, Yan, Li, Yang, et al. .BMC HEALTH SERVICES RESEARCH. 2019, 19.